Juniper Pharmaceuticals Inc.
www.juniperpharma.com
Latest From Juniper Pharmaceuticals Inc.
Pipeline Review: Large Potential Overactive Bladder Population Beckons
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Execs On The Move, January 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Execs On The Move, May 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
-
Biotechnology
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
-
Drug Delivery
- Services
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Alias(es)
- Columbia Laboratories Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Juniper Pharmaceuticals Inc.
- Senior Management
-
Alicia Secor , Pres. & CEO
Jeffrey Young, CFO, Treasurer & Secretary
Nikin Patel, PhD, COO
Shen Luk, PhD, CSO - Contact Info
-
Juniper Pharmaceuticals Inc.
Phone: (617) 639-1500
33 Arch St., 31st Fl.
Ste. 3110
Boston, MA 02110
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juniper Pharmaceuticals Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice